{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:36:07Z","timestamp":1792647367984,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children's Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI090810"],"award-info":[{"award-number":["R01AI090810"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmcl.2024.129934","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T17:41:48Z","timestamp":1724866908000},"page":"129934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Enhancing the therapeutic window for Spectinamide anti-tuberculosis Agents: Synthesis, Evaluation, and activation of phosphate prodrug 3408"],"prefix":"10.1016","volume":"112","author":[{"given":"Jiuyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep B.","family":"Lukka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Ektnitphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur R.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Scherbakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Meibohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00earonique","family":"Dartois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik C.","family":"B\u00f6ttger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J.","family":"Lenaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129934_b0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.addr.2016.04.026","article-title":"New agents for the treatment of drug-resistant Mycobacterium tuberculosis","volume":"102","author":"Hoagland","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmcl.2024.129934_b0010","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2024.129934_b0015","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1473-3099(19)30489-X","article-title":"BPaL approved for multidrug-resistant tuberculosis","volume":"19","author":"Burki","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmcl.2024.129934_b0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nm.3458","article-title":"Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux","volume":"20","author":"Lee","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2024.129934_b0025","first-page":"770","article-title":"Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models","volume":"72","author":"Robertson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2024.129934_b0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1021\/acsinfecdis.6b00158","article-title":"Structure-activity relationships of spectinamide antituberculosis agents: a dissection of ribosomal inhibition and native efflux avoidance contributions","volume":"3","author":"Liu","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2024.129934_b0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tube.2018.12.006","article-title":"Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice","volume":"114","author":"Rathi","year":"2019","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.bmcl.2024.129934_b0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11095-019-2666-8","article-title":"Development and characterization of a dry powder formulation for anti-tuberculosis drug spectinamide 1599","volume":"36","author":"Stewart","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmcl.2024.129934_b0045","doi-asserted-by":"crossref","unstructured":"Bauman AA, Sarathy JP, Kaya F, et al. Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis. bioRxiv. 2024.","DOI":"10.1101\/2024.05.13.593953"},{"key":"10.1016\/j.bmcl.2024.129934_b0050","doi-asserted-by":"crossref","first-page":"e0174420","DOI":"10.1128\/AAC.01744-20","article-title":"Model-based exposure-response assessment for spectinamide 1810 in a mouse model of tuberculosis","volume":"65","author":"Wagh","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2024.129934_b0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.phrs.2010.04.004","article-title":"Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it?","volume":"62","author":"Balakumar","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmcl.2024.129934_b0060","doi-asserted-by":"crossref","unstructured":"Ali MZ, Dutt TS, MacNeill A, et al. A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides. bioRxiv. 2023.","DOI":"10.1101\/2023.11.16.567434"},{"key":"10.1016\/j.bmcl.2024.129934_b0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2174\/0929867330666230209094738","article-title":"Phosphate prodrugs: an approach to improve the bioavailability of clinically approved drugs","volume":"31","author":"Tantra","year":"2024","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2024.129934_b0070","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1021\/acsomega.0c05589","article-title":"Spirocycle MmpL3 inhibitors with improved hERG and cytotoxicity profiles as inhibitors of mycobacterium tuberculosis growth","volume":"6","author":"Ray","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2024.129934_b0075","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/acsinfecdis.0c00252","article-title":"Synthesis, structure-activity relationship, and mechanistic studies of aminoquinazolinones displaying antimycobacterial activity","volume":"6","author":"Akester","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2024.129934_b0080","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1128\/AAC.00055-06","article-title":"Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis","volume":"51","author":"Cho","year":"2007","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T21:43:02Z","timestamp":1726350182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24003366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":16,"alternative-id":["S0960894X24003366"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129934","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing the therapeutic window for Spectinamide anti-tuberculosis Agents: Synthesis, Evaluation, and activation of phosphate prodrug 3408","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129934"}}